The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Myeloid Cells Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    212

  • View Count
    1392

Example Insights

Myeloid Cells Targeting Therapeutics Market-Context Myeloid Cells Targeting Therapeutics Market-Development-Pipeline Myeloid Cells Targeting Therapeutics Market-Distribution-by-Type-of-Molecule Myeloid Cells Targeting Therapeutics Market-Publication-Analysis
Myeloid Cells Targeting Therapeutics Market-Clinical-Trial-Analysis Myeloid Cells Targeting Therapeutics Market-Partnerships-and-Collaborations Myeloid Cells Targeting Therapeutics Market-Funding-and-Investments Myeloid Cells Targeting Therapeutics Market-Academic-Grants-Analysis
Myeloid Cells Targeting Therapeutics Market-Case-Study Myeloid Cells Targeting Therapeutics Market-Start-up-Health-Indexing Myeloid Cells Targeting Therapeutics Market-Distribution-by-Geography  

Overview

With over 19 million new cancer cases and 10 million deaths reported in the year 2020, the global cancer burden continues to increase rapidly. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils, to sustain an immunosuppressive environment. Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. Targeting these cells help in modulating cancer-associated activities, including immune evasion. Therefore, myeloid therapies have gained significant attention as a potential adjunct to currently used therapies, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation to enhance therapeutic response. In addition, myeloid cell targeting therapies are being investigated for their potential in the treatment of various inflammatory disorders. 

Presently, several medical researchers and industry stakeholders are engaged in the development of therapeutics targeting myeloid cells that harness the immune system in order to treat a number of solid tumors, leukemias and some rare conditions, including myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from the ongoing studies and completed trials suggest that targeting of myeloid cells results in the delayed progression of solid tumors, thereby increasing the survival rate of the patients. Given the encouraging results, the domain has attracted the attention of many private and public investors who have invested around USD 4.9 billion over the last few years. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the myeloid cells targeting therapeutics market is anticipated to grow at a commendable pace in the mid to long-term.

Scope of the Report

The “Myeloid Cells Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035” report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the myeloid cells targeting therapeutics market. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the report includes:

  • A detailed assessment of the current market landscape of myeloid cells targeting therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), type of molecule (small molecules and biologics), target indication, therapeutic area (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of myeloid cells targeting therapeutics, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of myeloid cells targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
  • A detailed analysis of completed and ongoing clinical trials of various myeloid cells targeting therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.
  • A detailed review of more than 10,000 peer-reviewed, scientific articles related to research on myeloid cells targeting therapeutics, based on parameters, such as year of publication, emerging focus area, type of publication, therapeutic area, and target indication. The chapter also highlights the top journals and top authors (in terms of number of articles published).
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to myeloid cell targeting therapeutics, during the period, 2017-2021, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • An analysis of the partnerships that have been established in this domain since 2017, covering instances of  research and development agreement, clinical trials agreement, merger / acquisition, product development and commercialization agreement, licensing agreement, asset acquisition and product development and manufacturing agreement. 
  • A detailed analysis of the various investments made since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding in the companies focused on the development of myeloid cells targeting therapeutics.
  • An analysis of start-ups / small companies engaged in the development of myeloid cells targeting therapeutics, based on parameters, such as pipeline strength, pipeline maturity, indication diversity, financial support, number of investors, partnership activity and start-up health indexing.
  • A case study on the companies developing macrophage-based therapeutics, along with analyses on phase of development, type of molecule, target indication and therapeutic area. In addition, the chapter provides information on the year of establishment, company size and location of headquarters of the companies engaged in the development of these therapeutics.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with myeloid cell targeting therapeutics in the mid to long term. Based on parameters, such as adoption trends, and expected price variations for these products, we have developed informed estimates on the evolution of the market for the period 2021-2035. Our year wise projections of the current and forecasted opportunity within the myeloid cell targeting therapeutics market, have further been segmented across [A] type of molecule (small molecule and biologics), [B] therapeutic area (oncological disorders and rare disorders), [C] route of administration (intravenous and oral route) and [D] geography (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Rene Hoet (Chief Scientific Officer, Montis Biosciences)
  • Tom Wilton (Chief Business Officer, Carisma Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of myeloid cells targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for myeloid cell targeting therapeutics?
  • What is the focus of various publications related to therapeutics targeting myeloid cells?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • How is the current and future opportunity, related to myeloid cells targeting therapeutics, likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of myeloid cells targeting therapeutics market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to myeloid cell lines, types of myeloid cells and their functions, origin, differentiation and identification. In addition, the chapter provides information on the multifaceted functions of myeloid cells, receptors controlling their migration and activation, recruitment of myeloid cells in tumor microenvironment, their role in tumor progression and suppression. Further, the chapter presents details on approaches to select and target myeloid cells in tumor microenvironment, role of myeloid cells in different therapies, factors affecting their therapeutic efficacy, along with the challenges associated with myeloid cell targeting and the future perspectives.

Chapter 4 provides an overview of the current market landscape of myeloid cells targeting therapeutics, including analyses based on several relevant parameters, such as phase of development (clinical and preclinical), type of molecule (small molecules and biologics), target indication(s), therapeutic area (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders and others), biological targets, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of myeloid cells targeting therapeutics, along with information on their year of establishment, company size and location of headquarters.

Chapter 5 includes detailed profiles of key players engaged in the development of  myeloid cells targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.

Chapter 6 provides information on more than 1,500 completed and ongoing clinical studies of myeloid cells targeting therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.

Chapter 7 features a detailed review of more than 10,000 peer-reviewed, scientific articles related to research on myeloid cells targeting therapeutics, based on parameters, such as year of publication, emerging focus area, type of publication, therapeutic area, and target indication. The chapter also highlights the top journals and top authors (in terms of number of articles published).

Chapter 8 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to myeloid cells targeting therapeutics, during the period, 2017- 2021, on the basis of important parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization, study section and type of grant application. The chapter also highlights the popular recipient organizations (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 9 features an analysis of the partnerships that have been established in this domain, since 2017, covering instances of  research and development agreement, clinical trials agreement, merger / acquisition, product development and commercialization agreement, licensing agreement, asset acquisition and product development and manufacturing agreement. 

Chapter 10 presents a review of the funding and investments in this domain since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding. The chapter also includes a detailed analysis of funding and investment, based on several relevant parameters. 

Chapter 11 presents an analysis of the start-ups / small companies engaged in the development of myeloid cells targeting therapeutics, based on parameters, such as pipeline strength, pipeline maturity, indication diversity, financial support, number of investors, partnership activity and start-up health indexing.

Chapter 12 presents a case study on the companies developing macrophage-based therapeutics, along with analyses on phase of development, type of molecule, target indication, and therapeutic area. In addition, the chapter provides information on their year of establishment, company size and location of headquarters of the companies engaged in the development of these therapeutics.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of myeloid cell targeting therapeutics market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across (A) type of molecule (small molecule and biologics) (B) therapeutic area (oncological disorders and rare disorders) (C) route of administration (intravenous and oral route) and (D) geography (North America, Europe and Asia Pacific).

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented details of interviews held with (in alphabetical order) Rene Hoet (Chief Scientific Officer, Montis Biosciences) and Tom Wilton (Chief Business Officer, Carisma Therapeutics).

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Myeloid Cell Line
3.2. Origin, Differentiation and Identification of Myeloid Cells
3.3. Multifaceted Functions of Myeloid Cells
3.4. Receptors Controlling Migration and Activation of Myeloid Cells
3.5. Recruitment of Myeloid Cells in Tumor Microenvironment (TME)
3.6. Role of Myeloid Cells in Tumor Progression and Suppression
3.7. Approaches to Select and Target Myeloid Cells in TME
3.8. Myeloid Cells and Anti-tumor Therapies
3.9. Factors Affecting Therapeutic Efficacy of Myeloid Cell Targeting Therapeutics
3.10. Challenges Associated with Myeloid Cell Targeting
3.11. Future Perspectives

4. MYELOID CELLS TARGETING THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Myeloid Cells Targeting Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication(s)
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Biological Target(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Combination Drug(s)
4.2.9. Analysis by Line of Treatment
4.2.10. Analysis by Dosing Frequency

4.3. Myeloid Cells Targeting Therapeutics Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
4.3.5. Most Active Players: Analysis by Phase of Development of Drugs

5. MYELOID CELLS TARGETING THERAPEUTICS DEVELOPERS: COMPANY PROFILES
5.1. Companies with Drugs in Advanced Stages of Development
5.1.1. ChemoCentryx
5.1.1.1. Company Overview
5.1.1.2. Financial Information
5.1.1.3. Drug Portfolio
5.1.1.4. Recent Developments and Future Outlook

5.1.2. Daiichi Sankyo
5.1.2.1. Company Overview
5.1.2.2. Financial Information
5.1.2.3. Drug Portfolio
5.1.2.4. Recent Developments and Future Outlook

5.1.3. Gilead Sciences
5.1.3.1. Company Overview
5.1.3.2. Financial Information
5.1.3.3. Drug Portfolio
5.1.3.4. Recent Developments and Future Outlook

5.2. Companies with Multiple Therapeutic Development Programs
5.2.1. Janssen Biotech
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Drug Portfolio
5.2.1.4. Recent Developments and Future Outlook

5.2.2. Roche
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Drug Portfolio
5.2.2.4. Recent Developments and Future Outlook

5.2.3. Pfizer
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Drug Portfolio
5.2.3.4. Recent Developments and Future Outlook

5.2.4. GlaxoSmithKline
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Drug Portfolio
5.2.4.4. Recent Developments and Future Outlook

5.2.5. Macrophage Pharma
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Drug Portfolio
5.2.5.4. Recent Developments and Future Outlook

5.2.6. Enlivex
5.2.6.1. Company Overview
5.2.6.2. Financial Information
5.2.6.3. Drug Portfolio
5.2.6.4. Recent Developments and Future Outlook

5.2.7. Immune-Onc Therapeutics
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Drug Portfolio
5.2.7.4. Recent Developments and Future Outlook

5.2.8. Infinity Pharmaceuticals
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Drug Portfolio
5.2.8.4. Recent Developments and Future Outlook

5.2.9. AstraZeneca
5.2.9.1. Company Overview
5.2.9.2. Financial Information
5.2.9.3. Drug Portfolio
5.2.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIALS ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Myeloid Cells Targeting Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Type of Sponsor / Collaborator
6.2.4. Analysis by Registration Year and Type of Study
6.2.5. Analysis by Study Design
6.2.6. Analysis by Patient Enrollment
6.2.7. Year-wise Trend of Completed and Recruiting Trials
6.2.8. Analysis by Age Category
6.2.9. Analysis by Phase of Development and Trial Status
6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.2.12. Analysis by Trial Location
6.2.13. Analysis by Trial Status and Geography

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Myeloid Cells Targeting Therapeutics: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Emerging Focus Area
7.5. Analysis by Type of Publication
7.6. Analysis by Therapeutic Area
7.7. Analysis by Target Indication
7.8. Top Journals: Analysis by Number of Publications
7.9. Top Authors: Analysis by Number of Publications

8. ACADEMIC GRANTS ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Myeloid Cells Targeting Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Analysis by Type of Funding Institute Center
8.6. Popular NIH Departments: Analysis by Number of Grants
8.7. Analysis by Support Period
8.8. Analysis by Emerging Focus Area
8.9. Analysis by Purpose of Grants
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organization: Analysis by Number of Grants
8.14. Popular Recipient Organization: Analysis by Amount Awarded
8.15. Prominent Program Officers: Analysis by Number of Grants
8.16. Analysis by Study Section
8.17. Analysis by Type of Grant Application
8.18. Analysis by Funding Institute Center and Support Year

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Analysis Methodology and Key Parameters
9.2. Partnership Models
9.3. Myeloid Cells Targeting Therapeutics: List of Partnerships and Collaborations
9.4. Analysis by Year of Partnership
9.5. Analysis by Type of Partnership
9.6. Analysis by Year and Type of Partnership
9.7. Analysis by Type of Myeloid Cells Targeted
9.8. Analysis by Type of Molecule
9.9. Analysis by Therapeutic Area
9.10. Analysis by Type of Partner
9.11. Most Active Players: Analysis by Number of Partnerships
9.12. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Type of Funding
10.3. Myeloid Cells Targeting Therapeutics: List of Funding Instances
10.4. Analysis by Year of Funding
10.5. Analysis by Amount Invested
10.6. Analysis by Type of Funding
10.7. Analysis by Type of Funding and Amount Invested
10.8. Analysis by Year, Type of Funding and Amount Invested
10.9. Analysis by Type of Myeloid Cells Targeted
10.10. Analysis by Therapeutic Area
10.11. Analysis by Target Indication
10.12. Most Active Players: Analysis by Number of Funding Instances
10.13. Most Active Players: Analysis by Amount Invested
10.14. Key Investors: Analysis by Number of Funding Instances
10.15. Analysis by Geographical Regions
10.16. Analysis by Year and Type of Funding
10.17. Summary of Funding Instances

11. START-UP HEALTH INDEXING
11.1. Analysis Methodology and Key Parameters
11.2. Analysis by Pipeline Strength
11.3. Analysis by Pipeline Maturity
11.4. Analysis by Indication Diversity
11.5. Analysis by Financial Support
11.6. Analysis by Number of Investors
11.7. Analysis by Partnership Activity
11.8. Start-up Health Indexing: Roots Analysis Perspective

12. CASE STUDY: MACROPHAGE-BASED THERAPEUTICS DEVELOPERS
12.1 Overview and Key Parameters
12.2. Macrophage-based Therapeutics: List of Therapies
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Type of Molecule
12.2.3. Analysis by Target Indication(s)
12.2.4. Analysis by Therapeutic Area

12.3. Macrophage -based Therapeutic Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Assumptions
13.1. Global Myeloid Cells Targeting Therapeutics Market, 2021-2035
13.2. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Type of Molecule
13.2.1. Myeloid Cells Targeting Therapeutics Market for Small Molecules, 2021-2030
13.2.2. Myeloid Cells Targeting Therapeutics Market for Biologics, 2021-2030

13.3. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.2. Myeloid Cells Targeting Therapeutics Market for Rare Disorders, 2021-2030

13.4. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Route of Administration
13.4.1. Myeloid Cells Targeting Therapeutics Market for Intravenous Route, 2021-2030
13.4.2. Myeloid Cells Targeting Therapeutics Market for Oral Route, 2021-2030

13.5. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Geography
13.5.1. Myeloid Cells Targeting Therapeutics in North America, 2021-2030
13.5.2. Myeloid Cells Targeting Therapeutics in Europe, 2021-2030
13.5.3. Myeloid Cells Targeting Therapeutics in Asia Pacific, 2021-2030

14. EXECUTIVE INSIGHTS
14.1. Montis Bioscience
14.1.1. Company Snapshot
14.1.2. Interview Transcript: Rene Hoet (Chief Scientific Officer)

14.2. Carisma Therapeutics
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Tom Wilton (Chief Business Officer)

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Overview of Myeloid Cell Line
Figure 3.2 Origin, Differentiation and Identification of Myeloid Cells
Figure 3.3 Multifaceted Functions of Myeloid Cells
Figure 3.4 Recruitment of Myeloid Cells in Tumor Microenvironment (TME)
Figure 3.5 Role of Myeloid Cells in Tumor Progression and Suppression
Figure 3.6 Approaches to Select and Target Myeloid Cells in TME
Figure 3.7 Myeloid Cell and Anti-tumor Therapies
Figure 3.8 Factors Affecting Therapeutic Efficacy of Myeloid Cells Targeting Therapeutics
Figure 3.9 Challenges Associated with Myeloid Cell Targeting
Figure 3.10 Future Perspectives
Figure 4.1 Myeloid Cells Targeting Therapeutics: Distribution by Phase of Development
Figure 4.2 Myeloid Cells Targeting Therapeutics: Distribution by Type of Molecule
Figure 4.3 Myeloid Cells Targeting Therapeutics: Distribution by Phase of Development and Type of Molecule
Figure 4.4 Myeloid Cells Targeting Therapeutics: Distribution by Target Indications(s)
Figure 4.5 Myeloid Cells Targeting Therapeutics: Distribution by Therapeutic Area
Figure 4.6 Myeloid Cells Targeting Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.7 Myeloid Cells Targeting Therapeutics: Distribution by Biological Target(s)
Figure 4.8 Myeloid Cells Targeting Therapeutics: Distribution by Route of Administration
Figure 4.9 Myeloid Cells Targeting Therapeutics: Distribution by Type of Therapy
Figure 4.10 Myeloid Cells Targeting Therapeutics: Distribution by Combination Drug(s)
Figure 4.11 Myeloid Cells Targeting Therapeutics: Distribution by Line of Treatment
Figure 4.12 Myeloid Cells Targeting Therapeutics: Distribution by Dosing Frequency
Figure 4.13 Myeloid Cells Targeting Therapeutics Developers: Distribution by Year of Establishment
Figure 4.14 Myeloid Cells Targeting Therapeutics Developers: Distribution by Company Size
Figure 4.15 Myeloid Cells Targeting Therapeutics Developers: Distribution by Location of Headquarters and Company Size
Figure 4.16 Most Active Players: Distribution by Number of Therapeutic Programs
Figure 4.17 Most Active Players: Distribution by Highest Phase of Development of Drugs
Figure 5.1 ChemoCentryx: Financial Information
Figure 5.2 Daiichi Sankyo: Financial Information
Figure 5.3 Gilead Sciences: Financial Information
Figure 5.4 Janssen: Financial Information
Figure 5.5 Roche: Financial Information
Figure 5.6 Pfizer: Financial Information
Figure 5.7 GlaxoSmithKline: Financial Information
Figure 5.8 Infinity Pharmaceuticals: Financial Information
Figure 5.9 AstraZeneca: Financial Information
Figure 6.1 Clinical Trials Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trials Analysis: Distribution by Trial Registration Year
Figure 6.3 Clinical Trials Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.4 Clinical Trials Analysis: Distribution by Study Design
Figure 6.5 Clinical Trials Analysis: Distribution by Registration Year and Type of Study
Figure 6.6 Clinical Trials Analysis: Distribution by Patient Enrollment
Figure 6.7 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
Figure 6.8 Clinical Trials Analysis: Distribution by Age Category
Figure 6.9 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 6.10 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.11 Clinical Trials Analysis: Distribution by Trial Location
Figure 6.12 Clinical Trials Analysis: Distribution by Trial Status and Geography
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Publication Analysis: Distribution by Emerging Focus Area
Figure 7.3 Publication Analysis: Distribution by Type of Publication
Figure 7.4 Publication Analysis: Distribution by Therapeutic Area
Figure 7.5 Publication Analysis: Distribution by Target Indication
Figure 7.6 Top Journals: Distribution by Number of Publications
Figure 7.7 Top Authors: Distribution by Number of Publications
Figure 8.1 Academic Grants Analysis: Distribution by Year of Grants Awarded
Figure 8.2 Academic Grants Analysis: Distribution by Amount Awarded
Figure 8.3 Academic Grants Analysis: Distribution by Type of Funding Institute Center
Figure 8.4 Popular NIH Departments: Distribution by Number of Grants
Figure 8.5 Academic Grants Analysis: Distribution by Support Period
Figure 8.6 Academic Grants Analysis: Emerging Focus Area
Figure 8.7 Academic Grants Analysis: Distribution by Purpose of Grants
Figure 8.8 Academic Grants Analysis: Distribution by Grant Activity Code
Figure 8.9 Academic Grants Analysis: Distribution by Local Recipients
Figure 8.10 Academic Grants Analysis: Distribution by Type of Recipient Organization
Figure 8.11 Popular Recipient Organization: Distribution by Number of Grants
Figure 8.12 Popular Recipient Organization: Distribution by Amount Awarded
Figure 8.13 Prominent Program Officer: Distribution by Number of Grants
Figure 8.14 Academic Grants Analysis: Distribution by Study Section
Figure 8.15 Academic Grants Analysis: Distribution by Type of Grant Application
Figure 8.16 Academic Grants Analysis: Distribution by Funding Institute Center and Support Year
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Myeloid Cells Targeted
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investments: Distribution by Year of Funding
Figure 10.2 Funding and Investments: Distribution by Amount Invested
Figure 10.3 Funding and Investments: Distribution by Type of Funding
Figure 10.4 Funding and Investments: Distribution by Type of Funding and Amount Invested
Figure 10.5 Funding and Investments: Distribution by Year, Type of Funding and Amount Invested
Figure 10.6 Funding and Investments: Distribution by Type of Myeloid Cell
Figure 10.7 Funding and Investments: Distribution by Therapeutic Area
Figure 10.8 Funding and Investments: Distribution by Target Indication
Figure 10.9 Most Active Players: Distribution by Number of Funding Instances
Figure 10.10 Most Active Players: Distribution by Amount Invested
Figure 10.11 Key Investors: Distribution by Number of Funding Instances
Figure 10.12 Funding and Investments: Distribution by Geographical Regions
Figure 10.13 Funding and Investments: Distribution by Year of Establishment of Company and Type of Funding
Figure 10.14 Summary of Funding Instances
Figure 11.1 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 11.2 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 11.3 Start-up Health Indexing: Distribution by Indication Diversity
Figure 11.4 Start-up Health Indexing: Distribution by Financial Support
Figure 11.5 Start-up Health Indexing: Distribution by Number of Investors
Figure 11.6 Start-up Health Indexing: Distribution by Partnership Activity
Figure 11.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 12.1 Macrophage-based Therapeutics: Distribution by Phase of Development
Figure 12.2 Macrophage-based Therapeutics: Distribution by Type of Molecule
Figure 12.3 Macrophage-based Therapeutics: Distribution by Target Indication(s)
Figure 12.4 Macrophage-based Therapeutics: Distribution by Therapeutic Area
Figure 12.5 Macrophage-based Therapeutics Developers: Distribution by Year of Establishment
Figure 12.6 Macrophage-based Therapeutics Developers: Distribution by Company Size
Figure 12.7 Macrophage-based Therapeutics Developers: Distribution by Location of Headquarters
Figure 13.1 Global Myeloid Cells Targeting Therapeutics Market, 2021-2035 (USD Million)
Figure 13.2 Myeloid Cells Targeting Therapeutics Market for Small Molecules, 2021-2035 (USD Million)
Figure 13.3 Myeloid Cells Targeting Therapeutics Market for Biologics, 2021-2035 (USD Million)
Figure 13.4 Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2035 (USD Million)
Figure 13.5 Myeloid Cells Targeting Therapeutics Market for Rare Disorders, 2021-2035 (USD Million)
Figure 13.6 Myeloid Cells Targeting Therapeutics Market for Intravenous Therapies, 2021-2035 (USD Million)
Figure 13.7 Myeloid Cells Targeting Therapeutics Market for Oral Therapies, 2021-2035 (USD Million)
Figure 13.8 Myeloid Cells Targeting Therapeutics Market in North America, 2021-2035 (USD Million)
Figure 13.9 Myeloid Cells Targeting Therapeutics Market in Europe, 2021-2035 (USD Million)
Figure 13.10 Myeloid Cells Targeting Therapeutics Market in Asia Pacific, 2021-2035 (USD Million)

List Of Tables

Table 4.1 Myeloid Cells Targeting Therapeutics: Marketed and Clinical Development Pipeline
Table 4.2 Myeloid Cells Targeting Therapeutics: List of Developers
Table 6.1 Myeloid Cells Targeting Therapeutics: List of Clinical Trials, till 2021
Table 7.1 Myeloid Cells Targeting Therapeutics: List of Publications, 2016-2021
Table 8.1 Myeloid Cells Targeting Therapeutics: List of Grants, till 2021
Table 9.1 Myeloid Cells Targeting Therapeutics: List of Partnerships and Collaborations, 2017-2021
Table 10.1 Myeloid Cells Targeting Therapeutics: List of Funding Instances, 2017-2021
Table 12.1 Macrophage-based Therapeutics: List of Therapies
Table 12.2 Macrophage-based Therapeutics: List of Developers

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 3SBio
  2. Abcam
  3. Abramson Cancer Center (University of Pennsylvania)
  4. Acerta Pharma
  5. Albert Einstein College of Medicine
  6. Alexandria Venture Investments
  7. Allen Discovery Center (Tufts University)
  8. Amgen
  9. Arcus Biosciences
  10. Array BioPharma (acquired by Pfizer)
  11. Astellas Pharma
  12. AstraZeneca
  13. Barzilai Medical Center
  14. Beckman Research Institute (City of Hope)
  15. BeiGene
  16. Bioblast Pharma
  17. BioCryst Pharmaceuticals
  18. Birmingham Veterans Administration Medical Center 
  19. Bristol-Myers Squibb
  20. BVF Partners
  21. California Institute for Regenerative Medicine
  22. Carisma Therapeutics
  23. CARMA Cell Therapies (a subsidiary of MaxCyte)
  24. Case Western Reserve University
  25. CATO SMS
  26. Cedars-Sinai Medical Center
  27. Celgene (a subsidiary of Bristol Myers Squibb)
  28. Cellics Therapeutics
  29. ChemoCentryx
  30. Chroma Therapeutics
  31. Cincinnati Children's Hospital Medical Center
  32. Cleveland Clinic Lerner College of Medicine (CCLCM)
  33. Columbia University
  34. Cowen
  35. Daiichi Sankyo
  36. Dana-Farber Cancer Institute
  37. Dompé 
  38. Duke University
  39. East China Normal University (ECNU)
  40. Eli Lilly
  41. Emory University
  42. Enlivex Therapeutics
  43. Feinberg School of Medicine (Northwestern University)
  44. Five Prime Therapeutics (acquired by Amgen)
  45. Gardiner Institute
  46. Genentech
  47. Genzyme
  48. Gilead Sciences
  49. GlaxoSmithKline
  50. Goldman Sachs 
  51. H.C. Wainwright 
  52. Hadassah Medical Organization
  53. Hospital for Sick Children (SickKids)
  54. Houston Methodist Hospital
  55. Huazhong University of Science and Technology (HUST)
  56. Icahn School of Medicine
  57. Idera Pharmaceuticals
  58. IDM Research Laboratory
  59. ImCheck Therapeutics
  60. Immune-Onc Therapeutics
  61. Infinity Pharmaceuticals
  62. Janssen
  63. Johns Hopkins University
  64. Jounce Therapeutics
  65. Kindeva Drug Delivery
  66. Kineta
  67. Kiq
  68. Kite Pharma (acquired by Gilead Sciences)
  69. Kyung Hee University
  70. Leidos Biomedical Research
  71. Lonza
  72. Macomics
  73. Macrophage Pharma
  74. Macrophage Therapeutics
  75. Massachusetts General Hospital
  76. Mayo Clinic
  77. McGovern Medical School ( University of Texas Health Science Center)
  78. MD Anderson Cancer Center
  79. MedImmune
  80. Medpace
  81. Memorial Sloan Kettering Cancer Center
  82. Merck
  83. Moffitt Cancer Center
  84. Montis Biosciences
  85. Mount Sinai Health System
  86. Myeloid Therapeutics
  87. National Cancer Institute (NCI)
  88. National Heart, Lung, and Blood Institute (NHLBI)
  89. National Institute of Allergy and Infectious Diseases (NIAID)
  90. National Institutes of Health Clinical Center (NIHCC)
  91. Ningxia Medical University
  92. Novartis
  93. NYU Langone Health
  94. Oncovir
  95. OrbiMed
  96. Pathios Therapeutics
  97. Perelman School of Medicine (University of Pennsylvania)
  98. Peter MacCallum Cancer Centre
  99. Pfizer
  100. Phio Pharmaceuticals
  101. Pionyr Immunotherapeutics
  102. Piper Sandler
  103. Prokarium
  104. Prostate Cancer UK
  105. Regeneron
  106. Resolution Therapeutics
  107. Roche
  108. Sackler School of Medicine (Tel Aviv University)
  109. Samsung Biologics
  110. Sanofi
  111. Seagen
  112. Second Military Medical University (SMMU)
  113. Shoreline Biosciences
  114. Silverback Therapeutics
  115. SVB Leerink
  116. Sygnature Discovery
  117. Taiho Pharmaceutical
  118. Takeda
  119. Tel Aviv University
  120. Texas A&M University Health Science Center
  121. The Institute Jean Godinot
  122. Thunder Biotech
  123. Trillium Therapeutics
  124. University of Alabama
  125. University of California
  126. University of Chicago
  127. University of Chinese Academy of Sciences 
  128. University of Edinburgh
  129. University of Michigan
  130. University of Minnesota
  131. University of Oxford
  132. University of Pennsylvania
  133. University of Pittsburgh
  134. University of Regensburg
  135. University of Sydney
  136. University of Texas
  137. University of Virginia
  138. V Foundation for Cancer Research
  139. Verseau Therapeutics
  140. ViiV Healthcare
  141. Washington University
  142. Wedbush Securities
  143. Weill Cornell Medical College
  144. Yale University

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com